Compare GSK plc (GSK) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Xylem, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: GSK plc is far larger — about 3.9× Xylem, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Xylem, Inc. for 50 Days on average.
| GSK | XYL | |
|---|---|---|
Market Cap | $91.88B | $23.81B |
Volume | 7,730,529 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $61.18 | $152.95 |
52-Week Low | $43.24 | $100.92 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | $25.59B |
Dividend Yield | 3.9% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
XYL trades at $101.99, up 0.16% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 27, 2026. Revenue grew to $9.04B in 2025, and net income margin improved to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by solid fundamentals and a consensus price target of $149.13, implying significant upside. Risks include China market weakness and higher debt from recent note offerings. Analyst sentiment is mixed with 47.5% buy ratings, but institutional interest remains strong, as seen in Bank of America's new position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
